GlassScriptPhysician profile
William David Hottenstein
NPI 1588650154
$10,519.26
in general payments reported to CMS, 2019-2025
33 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $1,491 · 2021: $1,433 · 2022: $1,350 · 2023: $1,615 · 2024: $1,352 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,404 · Education: $15.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,403.57 |
| Education | $15.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,249.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,079.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,074.26 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $805.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $796.74 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $761.88 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.84 | 2019-2023 | Tradjenta, Jardiance |
| Daiichi Sankyo INC. | $543.73 | 2019-2022 | |
| Amgen INC. | $522.64 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $487.73 | 2019-2025 | |
| Amarin Pharma, INC. | $455.22 | 2019-2021 | |
| Exact Sciences Corporation | $262.19 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $225.35 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $219.44 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Radius Health, INC. | $199.12 | 2021-2025 | Tymlos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $170.70 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.64 | 2021-2025 | Xifaxan |
| Allergan, INC. | $133.08 | 2020 | |
| Novartis Pharmaceuticals Corporation | $128.65 | 2019-2023 | |
| Abbott Laboratories | $119.04 | 2022-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $114.77 | 2021-2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $104.56 | 2024-2025 | Voquezna |
| Dexcom, INC. | $82.66 | 2023-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $59.56 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $48.44 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $38.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.15 | 2022 | |
| Ibsa Pharma INC. | $18.16 | 2019 | |
| Teleflex LLC | $17.98 | 2024 | Urolift |
| Sumitomo Pharma America, INC. | $17.50 | 2025 | Gemtesa |
| Ani Pharmaceuticals, INC. | $16.87 | 2025 | Purified Cortrophin Gel |
| Biogen, INC. | $16.07 | 2022 | |
| Inspire Medical Systems, INC. | $15.20 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hottenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.